Trial Profile
Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant-mesothelioma
- Focus Biomarker; Pharmacodynamics
- 21 Dec 2020 Status changed from not yet recruiting to recruiting.
- 06 Dec 2018 New trial record